Process Control, Automation, and PAT

CO2 Incubators

July 01, 2024

The VIOS family of incubators are known for optimal cell growth conditions and minimal contamination risk.

Streamlining Aseptic Processes through Automation

June 13, 2024

Leveraging automation advancements can help improve efficiency in aseptic processing and speed up commercialization of critical drug products.

Using Advanced Algorithms to Solve Formulation Challenges

June 09, 2024

Artificial intelligence and machine learning can help overcome poor solubility and bioavailability.

The Need for Automated and Standardized CGT Manufacturing (BIO 2024)

June 07, 2024

Lonza’s Joe Garrity and Jerry Jiang discuss the importance of not only automating CGT manufacturing, but also standardizing across processes.

Applying AI to Molecular Structure (BIO 2024)

June 06, 2024

Founder and CEO of Atomic AI, Raphael Townshend, explores AI’s usefulness as a tool to characterize molecular structure and advance molecule engineering.

The Intersection of Chemistry, Robotics, and AI in Drug Discovery (BIO 2024)

June 05, 2024

Lee Cronin, founder and CEO of Chemify, discusses the combination of digital chemistry, robotics, and AI in the drug discovery space.

Publisher's Note: Automating Processes

June 03, 2024

Improved efficiencies and reduced costs are clear advantages of automating drug manufacturing processes.

CGT Catapult and Cellular Origins Team Up to Develop Automated CGT Manufacturing

June 01, 2024

CGT Catapult will implement Cellular Origins' robotic platform in its Stevenage, UK, site to establish automated CGT manufacturing.

Shoring Up Data Integrity Practices

May 06, 2024

Digital transformation is allowing for better handling, analysis, and protection of vast data collection.

Bristol Myers Squibb to Access Cellares' Cell Therapy Manufacturing Platform in New $380 Million CAR-T Cell Therapy Deal

April 24, 2024

In a new agreement, Cellares will utilize its Cell Shuttle fully automated cell therapy manufacturing platform to manufacture select CAR-T cell therapies under development by Bristol Myers Squibb.